Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): A multi-country, non-interventional, prospective cohort study among patients with human growth hormone (hGH) treatments under routine clinical care
Pfizer PROGRES registry
What is the goal of the study?
The purpose of this multi-country, non-interventional prospective cohort study among patients treated according to routine clinical practice, will be to assess the long-term safety and effectiveness of Genotropin, other daily human growth hormone (hGH) treatments, and Ngenla, a long-acting hGH, once granted marketing authorization and is commercially available, all of which is at the discretion of the treating physician according to routine clinical care.
Who can participate in the study?
Please contact the study team listed below to learn more.